Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Average PT from Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has received a consensus rating of “Hold” from the five research firms that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $13.75.

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday, February 25th.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is owned by insiders.

Institutional Trading of Theravance Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Aquatic Capital Management LLC bought a new stake in Theravance Biopharma during the fourth quarter worth about $25,000. Quantbot Technologies LP bought a new stake in Theravance Biopharma during the third quarter worth about $60,000. KLP Kapitalforvaltning AS bought a new stake in Theravance Biopharma during the fourth quarter worth about $69,000. China Universal Asset Management Co. Ltd. raised its holdings in Theravance Biopharma by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 3,696 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Theravance Biopharma during the fourth quarter worth about $103,000. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Trading Down 2.1 %

NASDAQ TBPH opened at $9.15 on Tuesday. The stock has a 50-day simple moving average of $9.32 and a 200 day simple moving average of $8.94. The company has a market capitalization of $449.94 million, a PE ratio of -9.06 and a beta of 0.21. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $18.75 million during the quarter, compared to analyst estimates of $29.90 million. As a group, sell-side analysts predict that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.